Patient Site
This site is intended for US Healthcare Providers only

Support and resources for generalized lipodystrophy (GL)

GL is a rare, complex, and clinically heterogeneous disorder characterized by the widespread lack or loss of subcutaneous adipose tissue in most or all parts of the body.


Resources for healthcare providers


GL Brochure

This brochure provides information about GL. Learn about clinical characteristics and serious comorbidities associated with GL.


Resources for patients

An informative website you can share with your patients to learn more about GL. In addition to covering information in the brochure above, patients can watch a helpful video to see personal stories of people living with GL.

Lipodystrophy Connect

Lipodystrophy Connect is a patient registry dedicated to generating sufficient data to better characterize the lipodystrophy patient community.

National Organization for Rare Disorders (NORD)

NORD provides advocacy, education, and other services to improve the lives of all people affected by rare diseases.

Office of Rare Disease Research (ORDR)

The ORDR identifies, coordinates, and supports research to help people who have any of the 8800 rare diseases known today.

Rare Disease Day

Rare Disease Day (February 28) recognizes and raises awareness of rare diseases across the globe. Visit the site to learn about the theme for this year’s event.

Lipodystrophy Day

March 31 is recognized as Global Lipodystrophy Day or World Day of Lipodystrophies. Visit the European Association of lipodystrophy website to learn about different ways to celebrate.

You are leaving the Aegerion Pharmaceuticals, Inc. website

You have selected a link to a site or an article written and published by persons not affiliated with Aegerion. The views expressed in the article are those of the author and do not reflect the views of Aegerion. Additionally, the information contained in these articles may no be current. Aegerion disavows any obligation to correct or to update the information contained in these articles.

You are leaving the Aegerion Pharmaceuticals, Inc. website. Do you wish to continue?